Cadrenal Therapeutics, Inc. Overview
Pro stress-test →Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The company targets orphan indications with narrow therapeutic windows where existing anticoagulants fail, representing a significant unmet medical need in rare cardiovascular and immune disorders.
Strategic Profile
Pro stress-test →Cadrenal develops novel and differentiated biopharmaceutical products to bridge essential gaps in currently available anticoagulation therapeutics. The company's 12-LOX inhibitor portfolio represents a differentiated platform approach across a range of thrombotic and inflammatory conditions, with both acute and chronic potential applications.
Competitive Landscape
Pro stress-test →Existing treatments such as warfarin and DOACs (Eliquis, Xarelto) often do not meet the needs of patients with orphan cardiovascular conditions, creating an addressable market gap. Cadrenal's tecarfarin and 12-LOX inhibitors target specific high-risk patient populations abandoned by conventional anticoagulants, differentiating it from large-cap pharma competitors focused on broader markets.
Industry Context
Cadrenal Therapeutics, Inc. operates in Biopharmaceuticals - Anticoagulation & Rare Cardiovascular Therapeutics.
Key facts
Headquarters: Ponte Vedra, US · Revenue: $0 · Market cap: $12.81M